Сравнение
Leuprorelin vs. Pasireotid
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Исследования (прочее)
Исследования (прочее)
Номер CAS
53714-56-0
396091-73-9
Молекулярная масса
1209.4 g/mol
1047.21 g/mol
Период полувыведения
3 h
нет данных
Последовательность
Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEtнет данных
Механизм действия
Leuprorelin
Leuprorelin is a GnRH-receptor agonist. After binding to pituitary GnRH receptors, it first causes a transient surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release — the so-called flare. With continuous, non-pulsatile exposure the receptors are downregulated and desensitized, suppressing gonadotropin secretion and consequently lowering sex steroids (testosterone or estradiol) to low levels. This mechanism underlies the literature-described use in hormone-dependent conditions.
Pasireotid
Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
4
1
из них на людях
4
1
Зафиксированные эффекты
4
2
Открытые противоречия
1
0
Задокументированные нежелательные явления
3
2
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Leuprorelin and Pasireotid?
- Leuprorelin is classified as "Исследования (прочее)", while Pasireotid is classified as "Исследования (прочее)". Leuprorelin: Leuprorelin (also leuprolide) is a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH). It is an approved prescription medicine in several jurisdictions, including for advanced prostate cancer, endometriosis, uterine fibroids and central precocious puberty. This page neutrally summarizes the evidence base and legal status and is not a usage or dosing recommendation. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Leuprorelin or Pasireotid?
- The highest available evidence level is "РКИ на людях" for Leuprorelin and "РКИ на людях" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Leuprorelin and Pasireotid in Germany and the United States?
- Германия: Leuprorelin — Рецептурный, Pasireotid — Рецептурный. США: Leuprorelin — Рецептурный, Pasireotid — Рецептурный. These are factual summaries with source and review date on the individual pages.